Industries > Pharma > Pharmaceutical Contract Manufacturing Market 2018-2028

Pharmaceutical Contract Manufacturing Market 2018-2028

Active Ingredient (API) and Finished Dose Formulation (FDF), Generic APIs, HPAPIs, Solid Dosages, Injectable Dosages

PUBLISHED: 27 June 2018
PAGES: 230
PRODUCT CODE: PHA0321
SUBMARKET: Contract Services

Clear
WOOCS 2.2.1
DOWNLOAD SAMPLE

The pharmaceutical contract manufacturing market is expected to grow at a CAGR of 6.0% in the first half of the forecast period. The API Manufacturing submarket held 66% of the market in 2017. Visiongain estimated that the pharmaceutical contract manufacturing market will reach $93bn in 2022.

How this report will benefit you
Read on to discover how you can exploit the future business opportunities emerging in this sector.

In this brand new 230-page report you will receive 77 tables and 58 figures– all unavailable elsewhere.

The 230-page report provides clear detailed insight into the pharmaceutical contract manufacturing market. Discover the key drivers and challenges affecting the market.
By ordering and reading our brand-new report today you stay better informed and ready to act.

Report Scope

• Global Pharmaceutical Contract Manufacturing Market forecasts from 2018-2028

• Submarket forecasts at world level, from 2018-2028:
Active pharmaceutical ingredients (APIs), with sub forecasts for generic APIs, high potency active pharma ingredients (HPAPIs) and other products
Finished dosage formulations (FDFs), with sub forecasts for solid dose forms, injectable dosages and other dosage types
Other applications of outsourced production – other related services

• Revenue forecasts from 2018-2028, for these regional and national markets:
• The US
• Canada
• Japan
• EU5: Germany, France, the UK, Italy and Spain
• BRIC: Brazil, Russia, India, China
• South Korea
• Turkey
• Mexico
• Others

Pharmaceutical Contract Manufacturing Market 2018-2028

• Assessment of selected leading companies that hold major market shares in the pharmaceutical contract manufacturing industry

• Qualitative Analysis from a CMO Perspective

• Qualitative Analysis from a Client Perspective

Visiongain’s study is intended for anyone requiring commercial analyses for the pharmaceutical contract manufacturing market. You find data, trends and predictions.

Buy our report today Pharmaceutical Contract Manufacturing Market 2018-2028: Active Ingredient (API) and Finished Dose Formulation (FDF), Generic APIs, HPAPIs, Solid Dosages, Injectable Dosages.

Visiongain is a trading partner with the US Federal Government
CCR Ref number: KD4R6

Download sample pages

Complete the form below to download your free sample pages for Pharmaceutical Contract Manufacturing Market 2018-2028


Download sample pages

Complete the form below to download your free sample pages for Pharmaceutical Contract Manufacturing Market 2018-2028


Latest Pharma news

“Oncology remains the largest disease area in the pharmaceutical business. The oncology market is dominated by big pharma companies and high price labels” says Visiongain report

Although price is still the most important competitive advantage for a biosimilar company, current discount rates are not enough to automatically convince the key stakeholders of a biosimilar’s value.

10 September 2019

READ

“Anti-Infective Agents market set to grow to $141bn by 2024” says new Visiongain report

The global anti-infective agents market is one that is driven by innovation. This is vital for maintaining the rich pipeline of anti-infective agents seen in the market today.

09 September 2019

READ

“Global thyroid gland disorder treatment market is anticipated to grow at a lucrative CAGR of 3.6% and anticipated to reach USD 3.21 Billion by 2029”, says Visiongain report.

Thyroid disease is one of today’s most prevalent hormonal illnesses. Hyperthyroidism, hypothyroidism, and thyroid nodules are the most common thyroid gland disorders.

05 September 2019

READ

“Global somatostatin analogs market is anticipated to grow at a lucrative CAGR of 5.3% and anticipated to reach USD 4.78 Bn by 2029”, says Visiongain report.

Somatostatin was used to diagnose gastrointestinal tract tumors and acromegaly in the clinical environment.

05 September 2019

READ

Categories

Category